Prescription opioids. I. metabolism and excretion patterns of oxycodone in urine following controlled single dose administration

Journal of Analytical Toxicology

Volumn 37, Issue 5, 2013, Pages 255-264

  Cone, Edward J ^a   Heltsley, Rebecca ^a   Black, David L ^b,c   Mitchell, John M ^d   LoDico, Charles P ^e   Flegel, Ronald R ^e  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Aegis Sciences Corporation   (United States)

^c VANDERBILT UNIVERSITY   (United States)

^d RTI INTERNATIONAL   (United States)

^e SUBSTANCE ABUSE AND MENTAL HEALTH SERVICES ADMINISTRATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OXYCODONE;

ADULT; AGED; ANTECUBITAL SORENESS; ARTICLE; DIZZINESS; DRUG DISPOSITION; DRUG EXCRETION; DRUG METABOLISM; DRUG URINE LEVEL; FEMALE; HUMAN; HYDROLYSIS; IRRITABILITY; JOINT SWELLING; LIQUID CHROMATOGRAPHY; MALE; NAUSEA; NORMAL HUMAN; PRESCRIPTION; PRURITUS; SIDE EFFECT; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY; URINALYSIS; VOMITING;

ADULT; ANALGESICS, OPIOID; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; EMPLOYMENT; FEMALE; HUMANS; MALE; MORPHINANS; OXYCODONE; OXYMORPHONE; SUBSTANCE ABUSE DETECTION; TANDEM MASS SPECTROMETRY; TIME FACTORS; WORKPLACE; YOUNG ADULT;

EID: 84883004626     PISSN: 01464760     EISSN: 19452403     Source Type: Journal    
DOI: 10.1093/jat/bkt031     Document Type: Article

References (27)

1. Substance Abuse and Mental Health Administration (2011) Results from the 2010 National Survey on Drug Use and Health: Summary of national findings. NSDUH, NDDUH Series H-41, HHS Publication No. SMA 11-4658.
2. Centers for Disease Control and Prevention (2010) Unintentional drug poisoning in the United States. Centers for Disease Control and Prevention, Atlanta, GA.
3. Stoops, W.W., Hatton, K.W., Lofwall, M.R., Nuzzo, P.A., Walsh, S.L. (2010) Intravenous oxycodone, hydrocodone, and morphine in recreational opioid users: Abuse potential and relative potencies. Psychopharmacology, 212, 193-203.
4. Pappagallo, M., Sokolowska, M. (2012) The implications of tamperresistant formulations for opioid rotation. Postgraduate Medicine, 124, 101-109.
5. Drug Enforcement Administration (2012) Established aggregate production quotas for schedule I and II controlled substances and established assessment of annual needs for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine for 2013. Federal Register, 77, 59980-59983.
6. Cone, E.J. (2006) Ephemeral profiles of prescription drug and formulation tampering: Evolving pseudoscience on the Internet. Drug and Alcohol Dependence, 83, S31-S39
7. Takala, A., Kaasalainen, V., Seppala, T., Kalso, E., Olkkola, K.T. (1997) Pharmacokinetic comparison of intravenous and intranasal administration of oxycodone. Acta Anaesthesiologica Scandinavica, 41, 309-312.
8. Lalovic, B., Kharasch, E., Hoffer, C., Risler, L., Liu-Chen, L.Y., Shen, D.D. (2006) Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: Role of circulating active metabolites. Clinical Pharmacology & Therapeutics, 79, 461-479.
9. Baldacci, A., Thormann, W. (2005) Analysis of oxycodol and noroxycodol stereoisomers in biological samples by capillary electrophoresis. Electrophoresis, 26, 1969-1977.
10. Lalovic, B., Phillips, B., Risler, L.L., Howald, W., Shen, D.D. (2004) Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes. Drug Metabolism and Disposition, 32, 447-454.
11. Heiskanen, T., Olkkola, K.T., Kalso, E. (1998) Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. Clinical Pharmacology & Therapeutics, 64, 603-611.
12. Poyhia, R., Seppala, T., Olkkola, K.T., Kalso, E. (1992) The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects. British Journal of Clinical Pharmacology, 33, 617-621.
13. Yee, D.A., Best, B.M., Atayee, R.S., Pesce, A.J. (2012) Observations on the urine metabolic ratio of oxymorphone to oxycodone in pain patients. Journal of Analytical Toxicology, 36, 232-238.
14. Benziger, D.P., Miotto, J., Grandy, R.P., Thomas, G.B., Swanton, R.E., Fitzmartin, R.D. (1997) A pharmacokinetic/pharmacodynamic study of controlled-release oxycodone. Journal of Pain and Symptom Management, 13, 75-82.
15. Leow, K.P., Cramond, T., Smith, M.T. (1995) Pharmacokinetics and pharmacodynamics of oxycodone when given intravenously and rectally to adult patients with cancer pain. Anesthesia and Analgesia, 80, 296-302.
16. Heltsley, R., Zichterman, A., Black, D.L., Cawthon, B., Robert, T., Moser, F. et al. (2010) Urine drug testing of chronic pain patients. II. Prevalence patterns of prescription opiates and metabolites. Journal of Analytical Toxicology, 34, 32-38.
17. Cone, E.J., Caplan, Y.H., Moser, F., Robert, T., Shelby, M.K., Black, D.L. (2009) Normalization of urinary drug concentrations with specific gravity and creatinine. Journal of Analytical Toxicology, 33, 1-7.
18. DHHS (2008) Mandatory guidelines for federal workplace drug testing programs: Notice. Federal Register, 73, 71858-71907.
19. Bush, D.M. (2008) The U.S. mandatory guidelines for federal workplace drug testing programs: Current status and future considerations. Forensic Science International, 174, 111-119.
20. Ishida, T., Oguri, K., Yoshimura, H. (1982) Determination of oxycodone metabolites in urines and feces of several mammalian species. Journal of Pharmacobiodynamics, 5, 521-525.
21. Smith, M.L., Hughes, R.O., Levine, B., Dickerson, S., Darwin, W.D., Cone, E.J. (1995) Forensic drug testing for opiates. VI. Urine testing for hydromorphone, hydrocodone, oxymorphone, and oxycodone with commercial opiate immunoassays and gas chromatographymass spectrometry. Journal of Analytical Toxicology, 19, 18-26.
22. Leow, K.P., Smith, M.T., Williams, B., Cramond, T. (1992) Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer. Clinical Pharmacology & Therapeutics, 52, 487-495.
23. Cone, E.J., Darwin, W.D., Buchwald, W.F., Gorodetzky, C.W. (1983) Oxymorphone metabolism and urinary excretion in human, rat, guinea pig, rabbit, and dog. Drug Metabolism and Disposition, 11, 446-450.
24. Cone, E.J., Lange, R., Darwin,W.D. (1998) In vivo adulteration: Excess fluid ingestion causes false-negative marijuana and cocaine urine test results. Journal of Analytical Toxicology, 22, 460-473.
25. Hutchinson, M.R., Menelaou, A., Foster, D.J., Coller, J.K., Somogyi, A.A. (2004) CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes. British Journal of Clinical Pharmacology, 57, 287-297.
26. Zhou, S.F., Xue, C.C., Yu, X.Q., Li, C., Wang, G. (2007) Clinically important drug interactions potentially involving mechanismbased inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Therapeutic Drug Monitoring, 29, 687-710.
27. Gaedigk, A., Bradford, L.D., Marcucci, K.A., Leeder, J.S. (2002) Unique CYP2D6 activity distribution and genotype-phenotype discordance in black Americans. Clinical Pharmacology & Therapeutics, 72, 76-89.